{"gene":"LAIR1","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":1997,"finding":"LAIR-1 is a 32 kDa transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two ITIMs. Cross-linking of LAIR-1 on NK cells recruits SHP-1 and SHP-2 phosphatases and results in strong inhibition of NK cell-mediated cytotoxicity. LAIR-1 does not recognize HLA class I molecules.","method":"Antibody cross-linking on NK cells, phosphatase recruitment assay, cytotoxicity assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational paper with functional assays (cross-linking, phosphatase recruitment, cytotoxicity), independently replicated in many subsequent studies","pmids":["9285412"],"is_preprint":false},{"year":2006,"finding":"Collagens are high-affinity functional ligands for LAIR-1. The interaction depends on conserved Gly-Pro-Hyp collagen repeats. Collagen binding directly inhibits immune cell activation in vitro, establishing collagens as the first extracellular matrix ligands for an inhibitory immune receptor.","method":"Binding assays (cell-free and cell-surface), functional immune cell activation assays in vitro","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding and functional assays, independently replicated across many subsequent studies","pmids":["16754721"],"is_preprint":false},{"year":2009,"finding":"Crystal structure of LAIR-1 was determined and its collagen-binding site was mapped by NMR titrations and mutagenesis. Key residues R59, E61, and W109 are essential for collagen interaction. These residues are conserved between LAIR-1 and the platelet collagen receptor GPVI, revealing an unanticipated common structural mechanism of collagen recognition.","method":"X-ray crystallography, NMR titrations, site-directed mutagenesis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus NMR and mutagenesis in a single rigorous study","pmids":["20007810"],"is_preprint":false},{"year":1999,"finding":"LAIR-1 functions as a negative regulator of BCR-mediated signaling in B cells. Simultaneous cross-linking of LAIR-1 and the BCR reduces intracellular Ca2+ increase evoked by BCR ligation. LAIR-1 expression is lost during B cell activation (germinal center B cells, plasmablasts, plasma cells).","method":"Co-cross-linking assay, intracellular calcium flux measurement, flow cytometry for expression profiling","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional calcium signaling assay plus expression profiling, single lab","pmids":["10540327"],"is_preprint":false},{"year":1998,"finding":"LAIR-1 (p40) cross-linking prevents differentiation of CD14+ monocytes into dendritic cells induced by GM-CSF. Engagement of LAIR-1 inhibits GM-CSF receptor-mediated intracellular calcium increases in CD14+ and CD14+CD34+ cells, suggesting LAIR-1 blocks GM-CSF receptor signaling.","method":"Antibody cross-linking, morphological and phenotypic analysis, intracellular calcium measurement","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional differentiation assay plus calcium signaling measurement, single lab","pmids":["9692876"],"is_preprint":false},{"year":2008,"finding":"LAIR-2, a secreted homolog of LAIR-1, binds collagen with high affinity in a hydroxyproline-dependent manner and acts as a competitive antagonist of LAIR-1 by preventing collagen binding to LAIR-1 and blocking LAIR-1 cross-linking in vitro.","method":"Surface plasmon resonance, flow cytometry binding assays, adhesion assays, LAIR-1 cross-linking inhibition assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (SPR, flow cytometry, adhesion assay) in single study","pmids":["18209062"],"is_preprint":false},{"year":2012,"finding":"C1q is a functional ligand for LAIR-1. C1q and its collagen-like tail bind LAIR-1 and LAIR-2 in cell-free systems and on the cell membrane, trigger phosphorylation of LAIR-1 ITIMs in monocytes, and mediate inhibition of monocyte-DC differentiation and IFN-α production by plasmacytoid DCs. These effects were reversed by LAIR-2 and by LAIR-1 siRNA knockdown.","method":"Cell-free binding assays, cell surface binding assays, ITIM phosphorylation assay, siRNA knockdown, functional DC differentiation and IFN-α production assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including siRNA rescue, binding assays, and functional readouts; independently confirmed in subsequent studies","pmids":["23093673"],"is_preprint":false},{"year":2015,"finding":"LAIR1 is essential for AML development. LAIR1 activates SHP-1, which acts as a phosphatase-independent signaling adaptor to recruit CAMK1, leading to activation of downstream CREB. This LAIR1-SHP-1-CAMK1-CREB pathway sustains survival and self-renewal of AML stem cells. Inhibition of LAIR1 expression abolishes leukemia development without affecting normal hematopoiesis.","method":"shRNA knockdown, in vivo leukemia development assays, co-immunoprecipitation, signaling pathway analysis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in vivo, pathway delineation by Co-IP, multiple downstream targets confirmed","pmids":["25915125"],"is_preprint":false},{"year":2011,"finding":"Tumor-expressed transmembrane collagens bind LAIR-1 and activate LAIR-1 inhibitory signaling. LAIR-1-Fc fusion proteins and LAIR-1-expressing cells bind tumor cell-expressed collagens. Knockdown of prolyl 4-hydroxylase (required for collagen folding) diminishes LAIR-1 binding. Overexpression of collagen XVII on target cells diminishes NK cell cytotoxic activity.","method":"LAIR-1-Fc fusion protein binding assays, collagen knockdown by shRNA, NK cell cytotoxicity assay, flow cytometry","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including knockdown specificity control and functional cytotoxicity assay, single lab","pmids":["21955987"],"is_preprint":false},{"year":2015,"finding":"C1q-mediated repression of monocytes is regulated through LAIR-1. C1q engagement of LAIR-1 enhances LAIR-1 ITIM phosphorylation and promotes interaction of LAIR-1 with SHP-1. C1q/LAIR-1 signaling inhibits nuclear translocation of IRF-3 and IRF-5 in CpG-stimulated monocytes, suppressing type I IFN production.","method":"LAIR-1 phosphorylation assay, Co-immunoprecipitation of LAIR-1 with SHP-1, nuclear translocation assay (IRF-3 and IRF-5)","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus nuclear translocation assay, single lab, two orthogonal methods","pmids":["25247291"],"is_preprint":false},{"year":2017,"finding":"Mice lacking LAIR-1 exhibit increased platelet counts, prolonged platelet half-life, and increased proplatelet formation. LAIR-1 deficiency in megakaryocytes leads to enhanced Src family kinase activity and downstream signaling through the GPVI-FcRγ-chain and integrin αIIbβ3, which is transmitted to platelets making them hyperreactive to collagen/GPVI agonists. LAIR-1 inhibits GPVI-FcRγ signaling in megakaryocytes.","method":"LAIR-1 knockout mouse model, platelet count/half-life measurements, proplatelet formation assay, signaling analysis (Src kinase activity), thrombus formation (FeCl3 carotid artery model)","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse with multiple orthogonal phenotypic and mechanistic readouts including in vivo thrombosis model","pmids":["28336561"],"is_preprint":false},{"year":2020,"finding":"Collagen-induced T cell exhaustion occurs through LAIR1. CD18 interaction with collagen upregulates LAIR1 expression on CD8+ T cells, and LAIR1 induces T cell exhaustion through SHP-1. LAIR2 overexpression or SHP-1 inhibition sensitizes resistant tumors to anti-PD-1 therapy. LOXL2 suppression (reducing collagen deposition) increases T cell infiltration and reduces exhausted T cells.","method":"Proteomic and RNA profiling, murine tumor models, LAIR2 overexpression, SHP-1 inhibition, LOXL2 knockdown, flow cytometry for T cell phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vivo models, genetic and pharmacological interventions, signaling mechanism identified","pmids":["32908154"],"is_preprint":false},{"year":2021,"finding":"LAIR1 interacts with the stromal factor Colec12 as a high-affinity ligand (identified by proteomic definition of the LAIR1 interactome). LAIR1 signaling (triggered by Collagen1 and Colec12) activates pathways associated with survival, proliferation, and differentiation in myeloid cells. LAIR1 deficiency reduces Ly6C- non-classical monocyte frequencies due to altered proliferation and apoptosis, and alters interstitial macrophage heterogeneity in the lung.","method":"Proteomic interactome profiling, Lair1-/- mouse model, flow cytometry for monocyte/macrophage subsets, proliferation and apoptosis assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomic interactome identification plus genetic KO model with multiple cellular phenotypic readouts","pmids":["34260887"],"is_preprint":false},{"year":2018,"finding":"Collagen type I degradation fragments inhibit osteoclast formation acting through LAIR-1. The inhibition requires LAIR-1, as collagen fragments failed to inhibit osteoclast formation from LAIR-1-deficient murine precursors. Collagen fragments signaled through SH-2 phosphatases, inhibiting calcium signaling and NFATc1 translocation in osteoclast precursors.","method":"LAIR-1 KO mouse osteoclast precursors, osteoclast differentiation assay, calcium signaling assay, NFATc1 nuclear translocation assay","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO rescue experiment demonstrating LAIR-1 specificity, plus signaling mechanism with two orthogonal readouts","pmids":["30217615"],"is_preprint":false},{"year":2021,"finding":"LAIR-1 is inducible on activated ILC2s and downregulates their cytokine secretion and effector function. LAIR-1 signaling in ILC2s is mediated via SHP1/PI3K/AKT inhibitory pathways. LAIR-1 deficiency leads to exacerbated ILC2-dependent airway hyperreactivity. Engagement of LAIR-1 by physiologic ligand C1q significantly reduced ILC2-dependent AHR in a humanized murine model.","method":"LAIR-1 knockout mice, adoptive transfer experiments, RNA sequencing, flow cytometry, antisense knockdown in human ILC2s, humanized mouse model","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, adoptive transfer, human knockdown with multiple orthogonal approaches and in vivo functional readouts","pmids":["34144112"],"is_preprint":false},{"year":2019,"finding":"LAIR-1 deficiency in mice enhances airway neutrophil recruitment and worsens inflammatory lung disease after RSV infection and cigarette smoke exposure. LAIR-1-Fc administration augments inflammation similarly. CXCL1-mediated neutrophil recruitment to airways is enhanced in LAIR-1-deficient mice, supporting an intrinsic function of LAIR-1 on neutrophils.","method":"Lair1-/- mouse model, RSV infection and cigarette smoke models, LAIR-1-Fc administration, intranasal CXCL1 challenge, cellular influx analysis","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus pharmacological blockade in two distinct in vivo models, consistent findings","pmids":["31080449"],"is_preprint":false},{"year":2015,"finding":"A LAIR1 insertion in antibody genes generates broadly reactive antibodies against malaria RIFINs. The insertion, encoding the entire 98 amino acid collagen-binding domain of LAIR1, is inserted between the V and DJ segments via interchromosomal DNA transposition. Somatic mutations in the LAIR1 domain abolish collagen binding and increase binding to infected erythrocytes. The LAIR1 domain is both necessary and sufficient for RIFIN binding.","method":"Monoclonal antibody isolation, sequencing of antibody genes, domain deletion/mutation analysis, binding assays to infected erythrocytes and RIFIN antigens","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — domain-level mutagenesis establishing necessity and sufficiency, confirmed in multiple donors and replicated by subsequent structural studies","pmids":["26700814"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the Fab fragment of a LAIR1-containing antibody was determined. The antigen-binding site positions the LAIR1 collagen-binding domain while the original Fab hypervariable loops are occluded, revealing a novel mechanism of antigen recognition in which the Fab acts as an adaptor linking the LAIR1 insert to constant antibody regions.","method":"X-ray crystallography of Fab fragment","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional interpretation, single study","pmids":["28527239"],"is_preprint":false},{"year":2021,"finding":"The structural basis of C1q collagen-like region (CLR) interaction with LAIR-1 was characterized. LAIR-1 interacts with C1q's CLR through a binding site close to but distinct from the C1r2s2 protease tetramer binding site. Site-directed mutagenesis identified LAIR-1 residues involved in C1q interaction.","method":"Recombinant protein production, binding assays, competition assays, site-directed mutagenesis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis with competition binding assays, single lab, no crystal structure","pmids":["34066122"],"is_preprint":false},{"year":2021,"finding":"Crystal structures of two RIFINs in complex with LAIR1 were determined. The RIFIN-binding sites on LAIR1 overlap with the collagen-binding site. RIFINs engage LAIR1 with different binding angles. RIFIN activation of LAIR1 induces LAIR1-mediated cell signaling, and LAIR1-containing antibodies can block this pathway.","method":"X-ray crystallography of RIFIN-LAIR1 complexes, functional cell signaling assay, antibody blocking assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of two independent complexes plus functional signaling validation; confirmed by independent structural study (PMID 34244481)","pmids":["34433057"],"is_preprint":false},{"year":2021,"finding":"Structures of RIFIN-V2 domain in complex with LAIR1 domain were determined by crystallography. The LAIR1-binding region of RIFIN is hydrophobic and membrane-distal, exhibits extensive structural diversity, and interacts with RIFIN-V2 in a one-to-one fashion. Essential elements of RIFIN-binding on LAIR1 were identified.","method":"Negative-stain EM, X-ray crystallography, sequence/structure analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures plus EM architecture determination in a single rigorous study","pmids":["34244481"],"is_preprint":false},{"year":2018,"finding":"LAIR-1 activation inhibits M1-like macrophage polarization and promotes alternative (M2) activation in human THP-1 macrophages. IFN-γ reduces LAIR-1 expression in THP-1 macrophages. IL-4 has no effect on LAIR-1 expression.","method":"THP-1 macrophage polarization model, cytokine treatment, LAIR-1 activation by cross-linking, phenotypic analysis","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional polarization assay, single lab, single cell line model","pmids":["29887420"],"is_preprint":false},{"year":2018,"finding":"Silencing LAIR-1 in THP-1 macrophages modulates the SHP-1/CREB/PPARγ pathway, promoting M2 macrophage polarization and increasing foam cell formation. LAIR-1 signaling through SHP-1 and CREB controls PPARγ expression and cholesterol metabolism.","method":"siRNA silencing of LAIR-1, western blotting for SHP-1/CREB activation, Oil Red O staining for foam cell formation, qPCR for PPARγ and cholesterol metabolism genes","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple pathway readouts, single lab","pmids":["30176557"],"is_preprint":false},{"year":2023,"finding":"LAIR1 drives glioma progression through SHP2-mediated FAK nuclear localization, resulting in increased transcription of cyclin D1 and chemokines/cytokines (CCL5, TGFβ2, IL33). The LAIR1 ITIMs recruit SHP2, which interacts with FAK and induces FAK nuclear localization. LAIR1Y251/281F (ITIMs mutant) and SHP2Q510E mutants significantly reduced FAK nuclear localization and target gene expression.","method":"Co-immunoprecipitation, nuclear/cytoplasm fractionation, ITIM mutagenesis, in vitro and in vivo glioma growth assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus mutagenesis with functional readouts, single lab","pmids":["37845206"],"is_preprint":false},{"year":2021,"finding":"Globular domain of adiponectin (gAdp) interacts with LAIR-1. In vitro experiments showed that gAdp inhibits T cell activation via LAIR-1 through a process involving downstream SHP-2.","method":"Pulldown/binding assay, T cell activation inhibition assay, SHP-2 downstream signaling analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single binding and functional experiment, single lab, limited mechanistic depth","pmids":["34403808"],"is_preprint":false},{"year":2017,"finding":"C1q can crosslink CD33 and LAIR-1 simultaneously and concurrently activate both inhibitory motifs. The globular region of C1q binds CD33, while the collagen-like region binds LAIR-1. Sialic acid masking of CD33 C2 domains regulates C1q-CD33 interactions.","method":"Binding assays, ITIM phosphorylation assay, siRNA-mediated knockdown, competition experiments with C1q domains","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain dissection with competition assays and ITIM phosphorylation readouts, single lab","pmids":["28325905"],"is_preprint":false},{"year":2013,"finding":"LAIR-1 inhibits osteoclastogenesis. Anti-LAIR-1 antibody treatment inhibits multinucleated osteoclast formation from mouse bone marrow cells in vitro. LAIR-1 overexpression in CD14+ monocytes also inhibits human osteoclastogenesis in vitro.","method":"Anti-LAIR-1 antibody treatment of bone marrow cultures, LAIR-1 overexpression in human monocytes, osteoclast differentiation assay","journal":"Clinics (Sao Paulo, Brazil)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both antibody blockade and overexpression approaches in two species, single lab","pmids":["23778340"],"is_preprint":false},{"year":2014,"finding":"Trophoblasts and decidual stromal cells regulate decidual NK cell function via secretion of collagen, which interacts with LAIR-1 on dNKs. Co-culture of dNKs with HTR-8/DSCs upregulates LAIR-1 and decreases perforin expression and Th1-type cytokine production. These effects are abrogated by LAIR-2 (competitive LAIR-1 inhibitor) and by collagen knockdown via shRNA.","method":"Co-culture assay, flow cytometry, ELISA for cytokines, shRNA knockdown of collagen, LAIR-2 competition assay","journal":"American journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple intervention approaches (LAIR-2 competition, shRNA), functional NK cell readouts, single lab","pmids":["24548186"],"is_preprint":false},{"year":2023,"finding":"LAIR-1 agonism by a therapeutic antibody (NC525) induces cell death of leukemic stem cells (LSCs) but not healthy hematopoietic stem cells. LAIR-1 agonism drives a unique apoptotic signaling program in leukemic cells, enhanced in the presence of collagen.","method":"Anti-LAIR-1 agonist antibody treatment, cell viability assays, cell-derived and patient-derived xenograft models, apoptosis signaling analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — agonist antibody with multiple in vitro and in vivo xenograft models, selectivity for LSC vs HSC demonstrated","pmids":["37966113"],"is_preprint":false},{"year":2024,"finding":"In HEL cells with JAK2 V617F mutation, LAIR-1 engagement with collagen recruits SHP-2, which downregulates tyrosine phosphorylation of JAK2, STAT1, STAT3, STAT5, AKT, and mTOR, thereby inhibiting cell proliferation and promoting apoptosis.","method":"Co-immunoprecipitation, western blotting for phosphorylation of pathway components, CCK-8 proliferation assay, flow cytometry apoptosis assay","journal":"Xi bao yu fen zi mian yi xue za zhi","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus multiple pathway phosphorylation assays with functional readouts, single lab","pmids":["38512030"],"is_preprint":false},{"year":2024,"finding":"LAIR1 increases PD-L1 expression in HCC cells through the GSK-3β/β-catenin/MYC/PD-L1 pathway, inducing exhaustion of infiltrating CD8+ T cells. LAIR1 in HCC cells induces phosphorylation of GSK-3β, impairing β-catenin expression and nuclear localization, thereby reducing MYC-mediated PD-L1 suppression and ultimately upregulating PD-L1.","method":"Western blot, immunofluorescence, nucleus/cytoplasm fractionation, co-culture of HCC cells with CD8+ T cells, flow cytometry for T cell exhaustion markers","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway assays with co-culture functional readout, single lab","pmids":["38199599"],"is_preprint":false},{"year":2025,"finding":"MARCO is a ligand for LAIR-1. MARCO interacts with LAIR-1 in trans on NK cells and induces LAIR-1 inhibitory signaling. MARCO and LAIR-1 also interact in cis on THP-1 macrophages (demonstrated by single-molecule fluorescence microscopy), reducing LAIR-1 binding to collagen and dampening LAIR-1 signaling. CRISPR-Cas9 knockout of MARCO in IL-10-polarized macrophages increases LAIR-1-mediated inhibitory function.","method":"Binding assays, LAIR-1 signaling assay on NK cells, single-molecule fluorescence microscopy, CRISPR-Cas9 knockout, collagen binding assay","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (single-molecule imaging, CRISPR KO, binding assays, functional signaling assay) in single rigorous study","pmids":["41364749"],"is_preprint":false},{"year":2024,"finding":"LAIR1 in HCC cells promotes migration and invasion through the AKT-IKKβ-p65 axis. LAIR1 also induces alternative activation and infiltration of tumor-associated macrophages via upregulation of IL-6 and CCL5 within this axis.","method":"Transwell/scratch migration assay, transcriptome sequencing, western blot, nucleus/cytoplasm fractionation, ELISA, cytokine microarray","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including transcriptome sequencing and functional migration assays, single lab","pmids":["39016636"],"is_preprint":false},{"year":2024,"finding":"LAIR-1 and PECAM-1 act to inhibit GPVI-mediated platelet activation via the same signaling pathway. LAIR-1/PECAM-1 double KO mice show platelets equally hyperresponsive to collagen as single KO mice. The enhanced Src family kinase activation previously shown in LAIR-1-deficient single KO mice is absent in DKO mice, suggesting functional redundancy through a shared pathway.","method":"LAIR-1/PECAM-1 double knockout mouse model, platelet aggregometry, flow cytometry, western blotting for Src signaling, FeCl3 thrombosis model","journal":"Research and practice in thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic double KO epistasis analysis with multiple functional and signaling readouts in vivo and in vitro","pmids":["39318773"],"is_preprint":false},{"year":2025,"finding":"PTIC (polymerized type I collagen) binds LAIR1 with affinity similar to collagen (confirmed by surface plasmon resonance). PTIC engagement of LAIR1 downregulates pSTAT1 (Tyr701) in IFN-γ-induced M1 macrophages, and reduces Mo1 monocyte subsets and associated cytokines in COVID-19 patients.","method":"Surface plasmon resonance binding assay, western blotting for pSTAT1, flow cytometry, clinical sample analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SPR binding confirmation plus functional signaling assay, single lab","pmids":["39940787"],"is_preprint":false},{"year":2024,"finding":"In fibrotic disease (systemic sclerosis), fibroblasts deposit disorganized collagen products that are dysfunctional LAIR-1 ligands, due to matrix metalloproteinase and PDGFR-dependent collagen remodeling. LAIR-1-deficient mice show increased skin fibrosis in two models, demonstrating that LAIR-1 is an essential negative feedback mechanism for tissue repair.","method":"LAIR-1 KO mouse models (repeated injury and bleomycin), fibroblast collagen deposition assay, MMP and PDGFR inhibitor experiments, LAIR-1 binding to patient-derived fibroblast matrix","journal":"Journal of autoimmunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in two independent mouse models plus mechanistic dissection in vitro with pharmacological inhibitors","pmids":["38696927"],"is_preprint":false},{"year":2020,"finding":"LAIR-1 suppresses ovarian cancer cell growth by inhibiting the PI3K-AKT-mTOR axis. Co-IP and mass spectrometry identified potential LAIR-1-binding proteins including eukaryotic translation initiation factors, suggesting LAIR-1 may also regulate protein synthesis at the translational level.","method":"LAIR-1 overexpression in SKOV3 cells, proliferation/migration/apoptosis assays, western blotting for PI3K/AKT/mTOR, Co-IP with mass spectrometry, in vivo tumor model","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS plus functional pathway assays in vitro and in vivo, single lab","pmids":["32628130"],"is_preprint":false},{"year":2018,"finding":"TNF-α stimulation causes shedding of cell-surface LAIR-1 from fibroblast-like synoviocytes via serine proteases. This shedding can be blocked by serine protease inhibitors. LAIR-1 overexpression in FLS reduces invasion and decreases mRNA levels of IL-6, IL-8, and MMP-13 in the presence of TNF-α.","method":"Flow cytometry for membrane LAIR-1, protease inhibitor experiments, qPCR, transwell invasion assay","journal":"Clinical and experimental immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological intervention identifying serine protease mechanism of shedding, plus functional invasion assay, single lab","pmids":["29328500"],"is_preprint":false},{"year":2024,"finding":"LAIR-1 inhibition (KO, antibody blockade, or 3-in-1 CAR) uncovered a LAIR1/factor XIII A/collagen IV immunosuppressive pathway across cancer types. LAIR1 inhibition induced phenotypic shift of M2-like macrophages toward M1 and enhanced CD8+ memory T cell populations, normalized tumor collagen IV in the TME.","method":"LAIR-1 KO mice, anti-LAIR-1 antibody blockade, 3-in-1 CAR T cell design, tumor models, flow cytometry, pathway analysis","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological interventions identifying a novel LAIR1/factor XIIIA/collagen IV pathway, single lab","pmids":["40591413"],"is_preprint":false}],"current_model":"LAIR-1 (CD305) is a broadly expressed immune inhibitory receptor with a single extracellular Ig-like domain and two cytoplasmic ITIMs that, upon engagement by extracellular matrix collagens (binding dependent on Gly-Pro-Hyp repeats), C1q (via its collagen-like tail), adiponectin globular domain, Colec12, or MARCO, recruits and activates the phosphatases SHP-1 and SHP-2, thereby dampening activating signals across NK cells, T cells, B cells, monocytes, dendritic cells, ILC2s, neutrophils, and megakaryocytes; in AML stem cells it additionally uses SHP-1 as a phosphatase-independent adaptor to recruit CAMK1 and activate CREB for survival/self-renewal, while in glioma and HCC tumor cells it recruits SHP2 to drive FAK nuclear localization and pro-tumorigenic transcriptional programs, and in megakaryocytes it restrains Src kinase activity in the same pathway as PECAM-1 to limit platelet reactivity; LAIR-2, a secreted homolog with higher collagen affinity, acts as a natural competitive antagonist of LAIR-1."},"narrative":{"mechanistic_narrative":"LAIR-1 (CD305) is a broadly expressed transmembrane immune inhibitory receptor with a single Ig-like domain and a cytoplasmic tail bearing two ITIMs that, upon cross-linking, recruits the phosphatases SHP-1 and SHP-2 to dampen activating signals — first established as a potent inhibitor of NK cell cytotoxicity [PMID:9285412]. Its defining feature is recognition of extracellular matrix: collagens are high-affinity functional ligands whose binding depends on Gly-Pro-Hyp repeats and engages a binding surface (R59, E61, W109) structurally analogous to the platelet collagen receptor GPVI [PMID:16754721, PMID:20007810]. Through this collagen sensing, LAIR-1 imposes inhibitory tone across diverse cell types — restraining BCR signaling in B cells, monocyte-to-DC differentiation, type I IFN production, ILC2 effector function via SHP1/PI3K/AKT, neutrophil recruitment, and osteoclastogenesis [PMID:10540327, PMID:23093673, PMID:34144112, PMID:31080449, PMID:30217615]. Beyond collagen, LAIR-1 is engaged by additional collagen-domain or stromal ligands including C1q (via its collagen-like tail), Colec12, adiponectin globular domain, MARCO, and polymerized type I collagen, with the secreted homolog LAIR-2 acting as a high-affinity competitive antagonist [PMID:18209062, PMID:23093673, PMID:34260887, PMID:34403808, PMID:41364749, PMID:39940787]. In the tissue setting LAIR-1 functions as a negative-feedback brake on tumor immunity and fibrosis: collagen-induced exhaustion of CD8+ T cells proceeds through LAIR1/SHP-1, and loss of functional collagen ligands in systemic sclerosis exacerbates fibrosis [PMID:32908154, PMID:38696927]. In cancer cells LAIR-1 is co-opted for pro-tumorigenic signaling — in AML stem cells SHP-1 acts as a phosphatase-independent adaptor recruiting CAMK1 to activate CREB for survival and self-renewal, while in glioma it recruits SHP2 to drive FAK nuclear localization and oncogenic transcription [PMID:25915125, PMID:37845206]. In megakaryocytes LAIR-1 restrains GPVI-FcRγ-driven Src family kinase activity in a pathway redundant with PECAM-1, limiting platelet reactivity [PMID:28336561, PMID:39318773]. The malaria RIFIN antigens engage LAIR1 at a site overlapping the collagen-binding surface, and somatic insertion of the LAIR1 collagen-binding domain into antibody genes generates broadly reactive anti-RIFIN antibodies [PMID:26700814, PMID:34433057].","teleology":[{"year":1997,"claim":"Established LAIR-1 as an HLA-independent inhibitory receptor, answering whether its ITIMs functionally couple to phosphatases and suppress effector function.","evidence":"Antibody cross-linking on NK cells with phosphatase recruitment and cytotoxicity assays","pmids":["9285412"],"confidence":"High","gaps":["Physiological ligand unknown at this point","Relative roles of SHP-1 vs SHP-2 not resolved"]},{"year":1999,"claim":"Extended LAIR-1 inhibitory function to B cell antigen receptor signaling and showed activation-dependent downregulation, defining its role across lymphocyte lineages.","evidence":"Co-cross-linking with BCR and intracellular calcium flux measurement plus expression profiling","pmids":["10540327"],"confidence":"Medium","gaps":["Downstream effectors in B cells not delineated","Single lab"]},{"year":1998,"claim":"Showed LAIR-1 blocks myeloid differentiation by inhibiting GM-CSF receptor signaling, broadening its inhibitory scope to monocyte/DC development.","evidence":"Antibody cross-linking with monocyte-DC differentiation and calcium measurement","pmids":["9692876"],"confidence":"Medium","gaps":["Mechanistic link to GM-CSFR signaling not molecularly defined","Single lab"]},{"year":2006,"claim":"Identified collagens as the first ECM ligands for an inhibitory immune receptor, answering the long-standing question of LAIR-1's physiological ligand.","evidence":"Cell-free and cell-surface binding assays with Gly-Pro-Hyp dependence and functional immune assays","pmids":["16754721"],"confidence":"High","gaps":["Structural basis of recognition not yet defined","In vivo relevance of collagen engagement untested"]},{"year":2009,"claim":"Defined the structural basis of collagen recognition and revealed an unexpected shared mechanism with the platelet receptor GPVI.","evidence":"X-ray crystallography, NMR titrations, and site-directed mutagenesis identifying R59/E61/W109","pmids":["20007810"],"confidence":"High","gaps":["Structure of receptor-ligand complex not solved","Conformational changes on engagement unknown"]},{"year":2008,"claim":"Identified the secreted homolog LAIR-2 as a higher-affinity competitive antagonist, establishing a natural mechanism for tuning LAIR-1 signaling.","evidence":"SPR, flow cytometry binding, adhesion, and cross-linking inhibition assays","pmids":["18209062"],"confidence":"High","gaps":["In vivo regulatory role of LAIR-2 not established"]},{"year":2012,"claim":"Broadened the LAIR-1 ligand repertoire to C1q via its collagen-like tail, linking complement to inhibitory signaling in myeloid cells.","evidence":"Binding assays, ITIM phosphorylation, siRNA knockdown, and functional DC/IFN-α assays","pmids":["23093673"],"confidence":"High","gaps":["Structural mode of C1q binding not yet defined here"]},{"year":2015,"claim":"Revealed a non-canonical, phosphatase-independent LAIR1-SHP-1-CAMK1-CREB axis sustaining AML stem cell survival, recasting an inhibitory receptor as a tumor dependency.","evidence":"shRNA knockdown, in vivo leukemia assays, Co-IP, and signaling pathway analysis","pmids":["25915125"],"confidence":"High","gaps":["Ligand driving the AML pathway not defined","How SHP-1 switches from phosphatase to adaptor unclear"]},{"year":2017,"claim":"Demonstrated that LAIR-1 restrains GPVI-FcRγ Src kinase signaling in megakaryocytes to limit platelet hyperreactivity and thrombosis.","evidence":"LAIR-1 KO mouse with platelet counts, proplatelet formation, Src activity, and in vivo thrombosis model","pmids":["28336561"],"confidence":"High","gaps":["Endogenous activating ligand in megakaryocytes not defined"]},{"year":2020,"claim":"Established collagen-LAIR1-SHP-1 as a driver of CD8+ T cell exhaustion and a checkpoint-resistance mechanism, linking matrix to anti-tumor immunity.","evidence":"Proteomic/RNA profiling, murine tumor models, LAIR2 overexpression, SHP-1 inhibition, LOXL2 knockdown","pmids":["32908154"],"confidence":"High","gaps":["Relative contribution of T-cell-intrinsic vs stromal LAIR1 not fully separated"]},{"year":2021,"claim":"Defined the LAIR1 interactome including Colec12 and extended its myeloid role to monocyte/macrophage homeostasis, while structural studies mapped C1q and RIFIN engagement.","evidence":"Proteomic interactome, Lair1-/- mice, flow cytometry; crystallography of RIFIN-LAIR1 complexes and C1q CLR mutagenesis","pmids":["34260887","34066122","34433057","34244481","34144112","34403808"],"confidence":"High","gaps":["Whether all newly identified ligands engage overlapping surfaces incompletely resolved","Adiponectin (gAdp) interaction rests on a single weaker study"]},{"year":2015,"claim":"Showed that the LAIR1 collagen-binding domain inserted into antibody genes confers broad anti-RIFIN reactivity, revealing pathogen exploitation and a novel antibody architecture.","evidence":"Monoclonal antibody isolation, antibody gene sequencing, domain mutagenesis, and erythrocyte/RIFIN binding; later Fab crystallography","pmids":["26700814","28527239"],"confidence":"High","gaps":["Frequency and selection of such insertions in the population not addressed here"]},{"year":2023,"claim":"Showed LAIR1 drives glioma progression via SHP2-mediated FAK nuclear localization and oncogenic transcription, and that agonist antibodies selectively kill leukemic stem cells.","evidence":"Co-IP, ITIM mutagenesis, fractionation, glioma models; agonist antibody NC525 with xenograft models","pmids":["37845206","37966113"],"confidence":"Medium","gaps":["Glioma mechanism from single lab","Generality of pro-tumor SHP2-FAK axis across tumor types untested"]},{"year":2024,"claim":"Established LAIR-1 as an essential negative-feedback brake on tissue repair and demonstrated functional redundancy with PECAM-1 in platelet signaling.","evidence":"LAIR-1 KO fibrosis models with MMP/PDGFR dissection; LAIR-1/PECAM-1 double KO epistasis with platelet aggregometry and Src signaling","pmids":["38696927","39318773"],"confidence":"High","gaps":["How disorganized fibrotic collagen loses LAIR-1 ligand activity at structural level not resolved"]},{"year":2024,"claim":"Delineated multiple tumor-cell-intrinsic LAIR1 signaling axes (GSK-3β/β-catenin/MYC/PD-L1; AKT-IKKβ-p65; SHP-2/JAK2-STAT) coupling LAIR1 to immune evasion and proliferation control.","evidence":"Western blot, fractionation, co-culture with CD8+ T cells, Co-IP, and migration/proliferation assays in HCC and HEL cells","pmids":["38199599","39016636","38512030"],"confidence":"Medium","gaps":["Each axis defined in a single lab/model","Reconciliation of inhibitory vs pro-tumor outcomes context-dependent"]},{"year":2025,"claim":"Identified MARCO as a bidirectional cis/trans regulator of LAIR-1 and confirmed polymerized collagen (PTIC) as a functional ligand, expanding the ligand and regulatory landscape.","evidence":"Single-molecule fluorescence microscopy, CRISPR-Cas9 KO, binding and signaling assays; SPR and pSTAT1 readouts for PTIC","pmids":["41364749","39940787"],"confidence":"High","gaps":["In vivo relevance of cis MARCO-LAIR1 regulation not established","PTIC therapeutic studies single lab"]},{"year":null,"claim":"How LAIR-1 switches between classical SHP-1/SHP-2-dependent inhibition and the phosphatase-independent or pro-tumorigenic signaling modes — and what determines this choice across cell types and ligands — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking ligand identity to SHP-1-adaptor vs phosphatase output","Structural basis of multi-ligand competition (collagen, C1q, MARCO, RIFIN) on one Ig domain incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,5]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[1,2]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,31,37]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,11,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,7,23]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[10,33]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[1,35]}],"complexes":[],"partners":["SHP-1","SHP-2","C1Q","COLEC12","MARCO","CAMK1","FAK","PECAM-1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6GTX8","full_name":"Leukocyte-associated immunoglobulin-like receptor 1","aliases":[],"length_aa":287,"mass_kda":31.5,"function":"Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation. May also play its inhibitory role independently of SH2-containing phosphatases. Modulates cytokine production in CD4+ T-cells, down-regulating IL2 and IFNG production while inducing secretion of transforming growth factor beta. Also down-regulates IgG and IgE production in B-cells as well as IL8, IL10 and TNF secretion. Inhibits proliferation and induces apoptosis in myeloid leukemia cell lines as well as prevents nuclear translocation of NF-kappa-B p65 subunit/RELA and phosphorylation of I-kappa-B alpha/CHUK in these cells. Inhibits the differentiation of peripheral blood precursors towards dendritic cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q6GTX8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LAIR1","classification":"Not Classified","n_dependent_lines":23,"n_total_lines":1208,"dependency_fraction":0.01903973509933775},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LAIR1","total_profiled":1310},"omim":[{"mim_id":"621105","title":"ETS VARIANT TRANSCRIPTION FACTOR 3-LIKE; ETV3L","url":"https://www.omim.org/entry/621105"},{"mim_id":"611162","title":"MALARIA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/611162"},{"mim_id":"606047","title":"LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 5; LILRA5","url":"https://www.omim.org/entry/606047"},{"mim_id":"605546","title":"GLYCOPROTEIN VI, PLATELET; GP6","url":"https://www.omim.org/entry/605546"},{"mim_id":"605341","title":"PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, ALPHA; PILRA","url":"https://www.omim.org/entry/605341"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":27.1},{"tissue":"lymphoid tissue","ntpm":44.5}],"url":"https://www.proteinatlas.org/search/LAIR1"},"hgnc":{"alias_symbol":["CD305","LAIR-1"],"prev_symbol":[]},"alphafold":{"accession":"Q6GTX8","domains":[{"cath_id":"2.60.40.10","chopping":"31-122","consensus_level":"high","plddt":96.7623,"start":31,"end":122}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6GTX8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6GTX8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6GTX8-F1-predicted_aligned_error_v6.png","plddt_mean":71.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LAIR1","jax_strain_url":"https://www.jax.org/strain/search?query=LAIR1"},"sequence":{"accession":"Q6GTX8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6GTX8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6GTX8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6GTX8"}},"corpus_meta":[{"pmid":"32908154","id":"PMC_32908154","title":"Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32908154","citation_count":333,"is_preprint":false},{"pmid":"9285412","id":"PMC_9285412","title":"LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9285412","citation_count":332,"is_preprint":false},{"pmid":"16754721","id":"PMC_16754721","title":"Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16754721","citation_count":268,"is_preprint":false},{"pmid":"18063695","id":"PMC_18063695","title":"The inhibitory collagen receptor LAIR-1 (CD305).","date":"2007","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/18063695","citation_count":233,"is_preprint":false},{"pmid":"23093673","id":"PMC_23093673","title":"C1q limits dendritic cell differentiation and activation by engaging LAIR-1.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23093673","citation_count":142,"is_preprint":false},{"pmid":"26700814","id":"PMC_26700814","title":"A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26700814","citation_count":134,"is_preprint":false},{"pmid":"18209062","id":"PMC_18209062","title":"The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18209062","citation_count":122,"is_preprint":false},{"pmid":"25915125","id":"PMC_25915125","title":"The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development.","date":"2015","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25915125","citation_count":118,"is_preprint":false},{"pmid":"35230974","id":"PMC_35230974","title":"Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35230974","citation_count":110,"is_preprint":false},{"pmid":"28847005","id":"PMC_28847005","title":"Public antibodies to malaria antigens generated by two LAIR1 insertion modalities.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28847005","citation_count":93,"is_preprint":false},{"pmid":"21955987","id":"PMC_21955987","title":"Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21955987","citation_count":88,"is_preprint":false},{"pmid":"10540327","id":"PMC_10540327","title":"Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10540327","citation_count":87,"is_preprint":false},{"pmid":"9692876","id":"PMC_9692876","title":"p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9692876","citation_count":76,"is_preprint":false},{"pmid":"15939744","id":"PMC_15939744","title":"Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes.","date":"2005","source":"Clinical and diagnostic laboratory immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15939744","citation_count":73,"is_preprint":false},{"pmid":"15950745","id":"PMC_15950745","title":"The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation.","date":"2005","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15950745","citation_count":71,"is_preprint":false},{"pmid":"36293412","id":"PMC_36293412","title":"Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36293412","citation_count":68,"is_preprint":false},{"pmid":"21151495","id":"PMC_21151495","title":"The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21151495","citation_count":67,"is_preprint":false},{"pmid":"34260887","id":"PMC_34260887","title":"Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1.","date":"2021","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/34260887","citation_count":60,"is_preprint":false},{"pmid":"17330824","id":"PMC_17330824","title":"Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17330824","citation_count":60,"is_preprint":false},{"pmid":"20007810","id":"PMC_20007810","title":"Crystal structure and collagen-binding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen binding by platelet receptor GPVI.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20007810","citation_count":60,"is_preprint":false},{"pmid":"22127695","id":"PMC_22127695","title":"Enhanced secretion of leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2) and soluble LAIR-1 in rheumatoid arthritis: LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than is soluble LAIR-1.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/22127695","citation_count":55,"is_preprint":false},{"pmid":"25247291","id":"PMC_25247291","title":"C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1).","date":"2015","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/25247291","citation_count":53,"is_preprint":false},{"pmid":"28325905","id":"PMC_28325905","title":"Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28325905","citation_count":49,"is_preprint":false},{"pmid":"33457088","id":"PMC_33457088","title":"Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1.","date":"2020","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/33457088","citation_count":42,"is_preprint":false},{"pmid":"31080449","id":"PMC_31080449","title":"LAIR-1 Limits Neutrophilic Airway Inflammation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31080449","citation_count":39,"is_preprint":false},{"pmid":"24380839","id":"PMC_24380839","title":"The role of LAIR-1 (CD305) in T cells and monocytes/macrophages in patients with rheumatoid arthritis.","date":"2013","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24380839","citation_count":39,"is_preprint":false},{"pmid":"34144112","id":"PMC_34144112","title":"LAIR-1 acts as an immune checkpoint on activated ILC2s and regulates the induction of airway hyperreactivity.","date":"2021","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34144112","citation_count":36,"is_preprint":false},{"pmid":"24415628","id":"PMC_24415628","title":"Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.","date":"2014","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/24415628","citation_count":36,"is_preprint":false},{"pmid":"24548186","id":"PMC_24548186","title":"Trophoblasts and decidual stromal cells regulate decidual NK cell functions via interaction between collagen and LAIR-1.","date":"2014","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/24548186","citation_count":35,"is_preprint":false},{"pmid":"29887420","id":"PMC_29887420","title":"LAIR-1 activation inhibits inflammatory macrophage phenotype in vitro.","date":"2018","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29887420","citation_count":34,"is_preprint":false},{"pmid":"36555775","id":"PMC_36555775","title":"LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36555775","citation_count":33,"is_preprint":false},{"pmid":"15350516","id":"PMC_15350516","title":"Establishment of an ELISA system for determining soluble LAIR-1 levels in sera of patients with HFRS and kidney transplant.","date":"2004","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/15350516","citation_count":32,"is_preprint":false},{"pmid":"36211388","id":"PMC_36211388","title":"Blocking LAIR1 signaling in immune cells inhibits tumor development.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36211388","citation_count":31,"is_preprint":false},{"pmid":"28336561","id":"PMC_28336561","title":"Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive Platelets.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28336561","citation_count":31,"is_preprint":false},{"pmid":"35562585","id":"PMC_35562585","title":"Understanding the contextual functions of C1q and LAIR-1 and their applications.","date":"2022","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35562585","citation_count":30,"is_preprint":false},{"pmid":"29776595","id":"PMC_29776595","title":"Clinicopathologic significance of LAIR-1 expression in hepatocellular carcinoma.","date":"2018","source":"Current problems in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29776595","citation_count":30,"is_preprint":false},{"pmid":"19283782","id":"PMC_19283782","title":"New assay to detect low-affinity interactions and characterization of leukocyte receptors for collagen including leukocyte-associated Ig-like receptor-1 (LAIR-1).","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19283782","citation_count":29,"is_preprint":false},{"pmid":"14559247","id":"PMC_14559247","title":"9.1C3 is identical to LAIR-1, which is expressed on hematopoietic progenitors.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14559247","citation_count":27,"is_preprint":false},{"pmid":"24399813","id":"PMC_24399813","title":"Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options?","date":"2014","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/24399813","citation_count":27,"is_preprint":false},{"pmid":"38448779","id":"PMC_38448779","title":"Lupus autoantibodies initiate neuroinflammation sustained by continuous HMGB1:RAGE signaling and reversed by increased LAIR-1 expression.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38448779","citation_count":26,"is_preprint":false},{"pmid":"30549148","id":"PMC_30549148","title":"LAIR-1 overexpression and correlation with advanced pathological grade and immune suppressive status in oral squamous cell carcinoma.","date":"2018","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/30549148","citation_count":26,"is_preprint":false},{"pmid":"37966113","id":"PMC_37966113","title":"LAIR-1 agonism as a therapy for acute myeloid leukemia.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37966113","citation_count":25,"is_preprint":false},{"pmid":"32690423","id":"PMC_32690423","title":"Role and mechanism of LAIR-1 in the development of autoimmune diseases, tumors, and malaria: A review.","date":"2020","source":"Current research in translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32690423","citation_count":22,"is_preprint":false},{"pmid":"32628130","id":"PMC_32628130","title":"LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32628130","citation_count":22,"is_preprint":false},{"pmid":"36344166","id":"PMC_36344166","title":"A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatment.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36344166","citation_count":21,"is_preprint":false},{"pmid":"30176557","id":"PMC_30176557","title":"Silencing LAIR-1 in human THP-1 macrophage increases foam cell formation by modulating PPARγ and M2 polarization.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/30176557","citation_count":21,"is_preprint":false},{"pmid":"30217615","id":"PMC_30217615","title":"Collagen type I degradation fragments act through the collagen receptor LAIR-1 to provide a negative feedback for osteoclast formation.","date":"2018","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/30217615","citation_count":21,"is_preprint":false},{"pmid":"33758859","id":"PMC_33758859","title":"Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical COVID-19 correlate with poor ISG response and upregulation of LAIR1 surface protein in PBMCs.","date":"2021","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33758859","citation_count":20,"is_preprint":false},{"pmid":"12757266","id":"PMC_12757266","title":"Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells.","date":"2003","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12757266","citation_count":19,"is_preprint":false},{"pmid":"37634572","id":"PMC_37634572","title":"LAIR-1 limits macrophage activation in acute inflammatory lung injury.","date":"2023","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37634572","citation_count":18,"is_preprint":false},{"pmid":"32563267","id":"PMC_32563267","title":"LAIR-1 overexpression inhibits epithelial-mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism.","date":"2020","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32563267","citation_count":18,"is_preprint":false},{"pmid":"23778340","id":"PMC_23778340","title":"Expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on osteoclasts and its potential role in rheumatoid arthritis.","date":"2013","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/23778340","citation_count":18,"is_preprint":false},{"pmid":"29083540","id":"PMC_29083540","title":"Incorporation of a Ligand Peptide for Immune Inhibitory Receptor LAIR-1 on Biomaterial Surfaces Inhibits Macrophage Inflammatory Responses.","date":"2017","source":"Advanced healthcare materials","url":"https://pubmed.ncbi.nlm.nih.gov/29083540","citation_count":18,"is_preprint":false},{"pmid":"31019980","id":"PMC_31019980","title":"Expression of LAIR-1 (CD305) on Human Blood Monocytes as a Marker of Hepatic Cirrhosis Progression.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31019980","citation_count":16,"is_preprint":false},{"pmid":"36810933","id":"PMC_36810933","title":"A novel mechanism of cannabidiol in suppressing ovarian cancer through LAIR-1 mediated mitochondrial dysfunction and apoptosis.","date":"2023","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36810933","citation_count":16,"is_preprint":false},{"pmid":"31843567","id":"PMC_31843567","title":"Signal inhibitory receptor on leukocytes (SIRL)-1 and leukocyte- associated immunoglobulin-like receptor (LAIR)-1 regulate neutrophil function in infants.","date":"2019","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/31843567","citation_count":16,"is_preprint":false},{"pmid":"31257148","id":"PMC_31257148","title":"Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31257148","citation_count":14,"is_preprint":false},{"pmid":"34066122","id":"PMC_34066122","title":"Molecular Basis of Complement C1q Collagen-Like Region Interaction with the Immunoglobulin-Like Receptor LAIR-1.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34066122","citation_count":14,"is_preprint":false},{"pmid":"28527239","id":"PMC_28527239","title":"The structure of a LAIR1-containing human antibody reveals a novel mechanism of antigen recognition.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28527239","citation_count":14,"is_preprint":false},{"pmid":"37845206","id":"PMC_37845206","title":"LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37845206","citation_count":13,"is_preprint":false},{"pmid":"34948139","id":"PMC_34948139","title":"1,25-Dihydroxyvitamin D3 and 20-Hydroxyvitamin D3 Upregulate LAIR-1 and Attenuate Collagen Induced Arthritis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34948139","citation_count":13,"is_preprint":false},{"pmid":"34403808","id":"PMC_34403808","title":"Adiponectin's globular domain inhibits T cell activation by interacting with LAIR-1.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34403808","citation_count":12,"is_preprint":false},{"pmid":"29328500","id":"PMC_29328500","title":"LAIR-1 shedding from human fibroblast-like synoviocytes in rheumatoid arthritis following TNF-α stimulation.","date":"2018","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29328500","citation_count":12,"is_preprint":false},{"pmid":"34433057","id":"PMC_34433057","title":"Structural basis of malarial parasite RIFIN-mediated immune escape against LAIR1.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34433057","citation_count":11,"is_preprint":false},{"pmid":"30844729","id":"PMC_30844729","title":"C1q contributes to post-stroke angiogenesis via LAIR1-HIF1α-VEGF pathway.","date":"2019","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/30844729","citation_count":11,"is_preprint":false},{"pmid":"38199599","id":"PMC_38199599","title":"LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38199599","citation_count":10,"is_preprint":false},{"pmid":"38648067","id":"PMC_38648067","title":"Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors.","date":"2024","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38648067","citation_count":10,"is_preprint":false},{"pmid":"31278068","id":"PMC_31278068","title":"Integrated OMICS platforms identify LAIR1 genetic variants as novel predictors of cross-sectional and longitudinal susceptibility to severe malaria and all-cause mortality in Kenyan children.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31278068","citation_count":10,"is_preprint":false},{"pmid":"15902436","id":"PMC_15902436","title":"Identification and characterization of the rat homologue of LAIR-1.","date":"2005","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15902436","citation_count":10,"is_preprint":false},{"pmid":"40425821","id":"PMC_40425821","title":"Inhibitory pattern recognition receptors: lessons from LAIR1.","date":"2025","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40425821","citation_count":7,"is_preprint":false},{"pmid":"38011310","id":"PMC_38011310","title":"LPS and type I and II interferons have opposing effects on epigenetic regulation of LAIR1 expression in mouse and human macrophages.","date":"2024","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/38011310","citation_count":6,"is_preprint":false},{"pmid":"38062469","id":"PMC_38062469","title":"Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis.","date":"2023","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38062469","citation_count":6,"is_preprint":false},{"pmid":"30486600","id":"PMC_30486600","title":"Low Expression of Leucocyte Associated Immunoglobulin Like Receptor-1 (LAIR-1/CD305) in a Cohort of Pediatric Acute Lymphoblastic Leukemia Cases.","date":"2018","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/30486600","citation_count":6,"is_preprint":false},{"pmid":"40591413","id":"PMC_40591413","title":"Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40591413","citation_count":5,"is_preprint":false},{"pmid":"39016636","id":"PMC_39016636","title":"LAIR1 promotes hepatocellular carcinoma cell metastasis and induces M2-macrophage infiltration through activating AKT-IKKβ-p65 axis.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39016636","citation_count":5,"is_preprint":false},{"pmid":"39318773","id":"PMC_39318773","title":"LAIR-1 and PECAM-1 function via the same signaling pathway to inhibit GPVI-mediated platelet activation.","date":"2024","source":"Research and practice in thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/39318773","citation_count":5,"is_preprint":false},{"pmid":"34244481","id":"PMC_34244481","title":"Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34244481","citation_count":5,"is_preprint":false},{"pmid":"39471525","id":"PMC_39471525","title":"Leukemic B cells expression of CD200 and Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1, CD305) in Chronic Lymphocytic Leukemia patients in relation to Treg frequency.","date":"2024","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/39471525","citation_count":5,"is_preprint":false},{"pmid":"39940787","id":"PMC_39940787","title":"Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39940787","citation_count":5,"is_preprint":false},{"pmid":"25234728","id":"PMC_25234728","title":"Comparison of LAIR-1 genetic pathways in murine vs human internal organs.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/25234728","citation_count":5,"is_preprint":false},{"pmid":"38696927","id":"PMC_38696927","title":"Impaired LAIR-1-mediated immune control due to collagen degradation in fibrosis.","date":"2024","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/38696927","citation_count":4,"is_preprint":false},{"pmid":"37647449","id":"PMC_37647449","title":"Effects of LAIR-1 on hepatocellular carcinoma cell proliferation and invasion via PI3K-AKT-mTOR pathway regulation.","date":"2023","source":"Immunity, inflammation and disease","url":"https://pubmed.ncbi.nlm.nih.gov/37647449","citation_count":4,"is_preprint":false},{"pmid":"39766129","id":"PMC_39766129","title":"Ulcerative Colitis, LAIR1 and TOX2 Expression, and Colorectal Cancer Deep Learning Image Classification Using Convolutional Neural Networks.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39766129","citation_count":3,"is_preprint":false},{"pmid":"39216164","id":"PMC_39216164","title":"Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses.","date":"2024","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/39216164","citation_count":3,"is_preprint":false},{"pmid":"40829176","id":"PMC_40829176","title":"Targeting LAIR1-mediated immunosuppression adds a new weapon to our immunotherapy arsenal.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40829176","citation_count":3,"is_preprint":false},{"pmid":"18394348","id":"PMC_18394348","title":"[The up-regulated expression of LAIR-1 in tumor patients PBMC].","date":"2008","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18394348","citation_count":3,"is_preprint":false},{"pmid":"17979548","id":"PMC_17979548","title":"Generation of rat monoclonal antibodies against murine LAIR-1.","date":"2007","source":"Hybridoma (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/17979548","citation_count":3,"is_preprint":false},{"pmid":"38915487","id":"PMC_38915487","title":"LAIR1 prevents excess inflammatory tissue damage in S. aureus skin infection and Cutaneous T-cell Lymphoma.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38915487","citation_count":2,"is_preprint":false},{"pmid":"24694245","id":"PMC_24694245","title":"A non-stimulatory monoclonal antibody against the inhibitory immunoreceptor LAIR-1.","date":"2014","source":"Monoclonal antibodies in immunodiagnosis and immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/24694245","citation_count":2,"is_preprint":false},{"pmid":"38933531","id":"PMC_38933531","title":"A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains.","date":"2024","source":"Antibody therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38933531","citation_count":2,"is_preprint":false},{"pmid":"40563506","id":"PMC_40563506","title":"The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40563506","citation_count":1,"is_preprint":false},{"pmid":"41364749","id":"PMC_41364749","title":"The scavenger receptor MARCO is a ligand for the immune inhibitory receptor LAIR-1 and regulates its function in cis.","date":"2025","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/41364749","citation_count":1,"is_preprint":false},{"pmid":"39031805","id":"PMC_39031805","title":"Utility of leukocyte-associated immunoglobulin-like receptor-1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B-cell non-Hodgkin lymphoma.","date":"2024","source":"Cytometry. Part B, Clinical cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/39031805","citation_count":1,"is_preprint":false},{"pmid":"39079337","id":"PMC_39079337","title":"CD305 participates in abnormal activation of memory CD4+ T cells in patients with RA and attenuates collagen-induced arthritis.","date":"2024","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39079337","citation_count":1,"is_preprint":false},{"pmid":"39753170","id":"PMC_39753170","title":"Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39753170","citation_count":1,"is_preprint":false},{"pmid":"38512030","id":"PMC_38512030","title":"[leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].","date":"2024","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38512030","citation_count":1,"is_preprint":false},{"pmid":"41153806","id":"PMC_41153806","title":"Intraepithelial Lymphocytes and LAIR1 Expression in Celiac Disease.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/41153806","citation_count":0,"is_preprint":false},{"pmid":"41231542","id":"PMC_41231542","title":"LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell Lymphoma.","date":"2025","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/41231542","citation_count":0,"is_preprint":false},{"pmid":"37292843","id":"PMC_37292843","title":"Lupus autoantibodies initiate a maladaptive equilibrium sustained by HMGB1:RAGE signaling and reversed by LAIR-1:C1q signaling.","date":"2023","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/37292843","citation_count":0,"is_preprint":false},{"pmid":"16143055","id":"PMC_16143055","title":"[Identification of cell lines expressing the putative ligand(s) for LAIR-1(CD305) and LAIR-2(CD306)].","date":"2005","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16143055","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50780,"output_tokens":9667,"usd":0.148673,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20004,"output_tokens":5010,"usd":0.112635,"stage2_stop_reason":"end_turn"},"total_usd":0.261308,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"LAIR-1 is a 32 kDa transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two ITIMs. Cross-linking of LAIR-1 on NK cells recruits SHP-1 and SHP-2 phosphatases and results in strong inhibition of NK cell-mediated cytotoxicity. LAIR-1 does not recognize HLA class I molecules.\",\n      \"method\": \"Antibody cross-linking on NK cells, phosphatase recruitment assay, cytotoxicity assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational paper with functional assays (cross-linking, phosphatase recruitment, cytotoxicity), independently replicated in many subsequent studies\",\n      \"pmids\": [\"9285412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Collagens are high-affinity functional ligands for LAIR-1. The interaction depends on conserved Gly-Pro-Hyp collagen repeats. Collagen binding directly inhibits immune cell activation in vitro, establishing collagens as the first extracellular matrix ligands for an inhibitory immune receptor.\",\n      \"method\": \"Binding assays (cell-free and cell-surface), functional immune cell activation assays in vitro\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding and functional assays, independently replicated across many subsequent studies\",\n      \"pmids\": [\"16754721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of LAIR-1 was determined and its collagen-binding site was mapped by NMR titrations and mutagenesis. Key residues R59, E61, and W109 are essential for collagen interaction. These residues are conserved between LAIR-1 and the platelet collagen receptor GPVI, revealing an unanticipated common structural mechanism of collagen recognition.\",\n      \"method\": \"X-ray crystallography, NMR titrations, site-directed mutagenesis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus NMR and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"20007810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"LAIR-1 functions as a negative regulator of BCR-mediated signaling in B cells. Simultaneous cross-linking of LAIR-1 and the BCR reduces intracellular Ca2+ increase evoked by BCR ligation. LAIR-1 expression is lost during B cell activation (germinal center B cells, plasmablasts, plasma cells).\",\n      \"method\": \"Co-cross-linking assay, intracellular calcium flux measurement, flow cytometry for expression profiling\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional calcium signaling assay plus expression profiling, single lab\",\n      \"pmids\": [\"10540327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"LAIR-1 (p40) cross-linking prevents differentiation of CD14+ monocytes into dendritic cells induced by GM-CSF. Engagement of LAIR-1 inhibits GM-CSF receptor-mediated intracellular calcium increases in CD14+ and CD14+CD34+ cells, suggesting LAIR-1 blocks GM-CSF receptor signaling.\",\n      \"method\": \"Antibody cross-linking, morphological and phenotypic analysis, intracellular calcium measurement\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional differentiation assay plus calcium signaling measurement, single lab\",\n      \"pmids\": [\"9692876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LAIR-2, a secreted homolog of LAIR-1, binds collagen with high affinity in a hydroxyproline-dependent manner and acts as a competitive antagonist of LAIR-1 by preventing collagen binding to LAIR-1 and blocking LAIR-1 cross-linking in vitro.\",\n      \"method\": \"Surface plasmon resonance, flow cytometry binding assays, adhesion assays, LAIR-1 cross-linking inhibition assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (SPR, flow cytometry, adhesion assay) in single study\",\n      \"pmids\": [\"18209062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"C1q is a functional ligand for LAIR-1. C1q and its collagen-like tail bind LAIR-1 and LAIR-2 in cell-free systems and on the cell membrane, trigger phosphorylation of LAIR-1 ITIMs in monocytes, and mediate inhibition of monocyte-DC differentiation and IFN-α production by plasmacytoid DCs. These effects were reversed by LAIR-2 and by LAIR-1 siRNA knockdown.\",\n      \"method\": \"Cell-free binding assays, cell surface binding assays, ITIM phosphorylation assay, siRNA knockdown, functional DC differentiation and IFN-α production assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including siRNA rescue, binding assays, and functional readouts; independently confirmed in subsequent studies\",\n      \"pmids\": [\"23093673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LAIR1 is essential for AML development. LAIR1 activates SHP-1, which acts as a phosphatase-independent signaling adaptor to recruit CAMK1, leading to activation of downstream CREB. This LAIR1-SHP-1-CAMK1-CREB pathway sustains survival and self-renewal of AML stem cells. Inhibition of LAIR1 expression abolishes leukemia development without affecting normal hematopoiesis.\",\n      \"method\": \"shRNA knockdown, in vivo leukemia development assays, co-immunoprecipitation, signaling pathway analysis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in vivo, pathway delineation by Co-IP, multiple downstream targets confirmed\",\n      \"pmids\": [\"25915125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tumor-expressed transmembrane collagens bind LAIR-1 and activate LAIR-1 inhibitory signaling. LAIR-1-Fc fusion proteins and LAIR-1-expressing cells bind tumor cell-expressed collagens. Knockdown of prolyl 4-hydroxylase (required for collagen folding) diminishes LAIR-1 binding. Overexpression of collagen XVII on target cells diminishes NK cell cytotoxic activity.\",\n      \"method\": \"LAIR-1-Fc fusion protein binding assays, collagen knockdown by shRNA, NK cell cytotoxicity assay, flow cytometry\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including knockdown specificity control and functional cytotoxicity assay, single lab\",\n      \"pmids\": [\"21955987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"C1q-mediated repression of monocytes is regulated through LAIR-1. C1q engagement of LAIR-1 enhances LAIR-1 ITIM phosphorylation and promotes interaction of LAIR-1 with SHP-1. C1q/LAIR-1 signaling inhibits nuclear translocation of IRF-3 and IRF-5 in CpG-stimulated monocytes, suppressing type I IFN production.\",\n      \"method\": \"LAIR-1 phosphorylation assay, Co-immunoprecipitation of LAIR-1 with SHP-1, nuclear translocation assay (IRF-3 and IRF-5)\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus nuclear translocation assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"25247291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Mice lacking LAIR-1 exhibit increased platelet counts, prolonged platelet half-life, and increased proplatelet formation. LAIR-1 deficiency in megakaryocytes leads to enhanced Src family kinase activity and downstream signaling through the GPVI-FcRγ-chain and integrin αIIbβ3, which is transmitted to platelets making them hyperreactive to collagen/GPVI agonists. LAIR-1 inhibits GPVI-FcRγ signaling in megakaryocytes.\",\n      \"method\": \"LAIR-1 knockout mouse model, platelet count/half-life measurements, proplatelet formation assay, signaling analysis (Src kinase activity), thrombus formation (FeCl3 carotid artery model)\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse with multiple orthogonal phenotypic and mechanistic readouts including in vivo thrombosis model\",\n      \"pmids\": [\"28336561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Collagen-induced T cell exhaustion occurs through LAIR1. CD18 interaction with collagen upregulates LAIR1 expression on CD8+ T cells, and LAIR1 induces T cell exhaustion through SHP-1. LAIR2 overexpression or SHP-1 inhibition sensitizes resistant tumors to anti-PD-1 therapy. LOXL2 suppression (reducing collagen deposition) increases T cell infiltration and reduces exhausted T cells.\",\n      \"method\": \"Proteomic and RNA profiling, murine tumor models, LAIR2 overexpression, SHP-1 inhibition, LOXL2 knockdown, flow cytometry for T cell phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vivo models, genetic and pharmacological interventions, signaling mechanism identified\",\n      \"pmids\": [\"32908154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LAIR1 interacts with the stromal factor Colec12 as a high-affinity ligand (identified by proteomic definition of the LAIR1 interactome). LAIR1 signaling (triggered by Collagen1 and Colec12) activates pathways associated with survival, proliferation, and differentiation in myeloid cells. LAIR1 deficiency reduces Ly6C- non-classical monocyte frequencies due to altered proliferation and apoptosis, and alters interstitial macrophage heterogeneity in the lung.\",\n      \"method\": \"Proteomic interactome profiling, Lair1-/- mouse model, flow cytometry for monocyte/macrophage subsets, proliferation and apoptosis assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomic interactome identification plus genetic KO model with multiple cellular phenotypic readouts\",\n      \"pmids\": [\"34260887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Collagen type I degradation fragments inhibit osteoclast formation acting through LAIR-1. The inhibition requires LAIR-1, as collagen fragments failed to inhibit osteoclast formation from LAIR-1-deficient murine precursors. Collagen fragments signaled through SH-2 phosphatases, inhibiting calcium signaling and NFATc1 translocation in osteoclast precursors.\",\n      \"method\": \"LAIR-1 KO mouse osteoclast precursors, osteoclast differentiation assay, calcium signaling assay, NFATc1 nuclear translocation assay\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO rescue experiment demonstrating LAIR-1 specificity, plus signaling mechanism with two orthogonal readouts\",\n      \"pmids\": [\"30217615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LAIR-1 is inducible on activated ILC2s and downregulates their cytokine secretion and effector function. LAIR-1 signaling in ILC2s is mediated via SHP1/PI3K/AKT inhibitory pathways. LAIR-1 deficiency leads to exacerbated ILC2-dependent airway hyperreactivity. Engagement of LAIR-1 by physiologic ligand C1q significantly reduced ILC2-dependent AHR in a humanized murine model.\",\n      \"method\": \"LAIR-1 knockout mice, adoptive transfer experiments, RNA sequencing, flow cytometry, antisense knockdown in human ILC2s, humanized mouse model\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, adoptive transfer, human knockdown with multiple orthogonal approaches and in vivo functional readouts\",\n      \"pmids\": [\"34144112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LAIR-1 deficiency in mice enhances airway neutrophil recruitment and worsens inflammatory lung disease after RSV infection and cigarette smoke exposure. LAIR-1-Fc administration augments inflammation similarly. CXCL1-mediated neutrophil recruitment to airways is enhanced in LAIR-1-deficient mice, supporting an intrinsic function of LAIR-1 on neutrophils.\",\n      \"method\": \"Lair1-/- mouse model, RSV infection and cigarette smoke models, LAIR-1-Fc administration, intranasal CXCL1 challenge, cellular influx analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus pharmacological blockade in two distinct in vivo models, consistent findings\",\n      \"pmids\": [\"31080449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A LAIR1 insertion in antibody genes generates broadly reactive antibodies against malaria RIFINs. The insertion, encoding the entire 98 amino acid collagen-binding domain of LAIR1, is inserted between the V and DJ segments via interchromosomal DNA transposition. Somatic mutations in the LAIR1 domain abolish collagen binding and increase binding to infected erythrocytes. The LAIR1 domain is both necessary and sufficient for RIFIN binding.\",\n      \"method\": \"Monoclonal antibody isolation, sequencing of antibody genes, domain deletion/mutation analysis, binding assays to infected erythrocytes and RIFIN antigens\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — domain-level mutagenesis establishing necessity and sufficiency, confirmed in multiple donors and replicated by subsequent structural studies\",\n      \"pmids\": [\"26700814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the Fab fragment of a LAIR1-containing antibody was determined. The antigen-binding site positions the LAIR1 collagen-binding domain while the original Fab hypervariable loops are occluded, revealing a novel mechanism of antigen recognition in which the Fab acts as an adaptor linking the LAIR1 insert to constant antibody regions.\",\n      \"method\": \"X-ray crystallography of Fab fragment\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional interpretation, single study\",\n      \"pmids\": [\"28527239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The structural basis of C1q collagen-like region (CLR) interaction with LAIR-1 was characterized. LAIR-1 interacts with C1q's CLR through a binding site close to but distinct from the C1r2s2 protease tetramer binding site. Site-directed mutagenesis identified LAIR-1 residues involved in C1q interaction.\",\n      \"method\": \"Recombinant protein production, binding assays, competition assays, site-directed mutagenesis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis with competition binding assays, single lab, no crystal structure\",\n      \"pmids\": [\"34066122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures of two RIFINs in complex with LAIR1 were determined. The RIFIN-binding sites on LAIR1 overlap with the collagen-binding site. RIFINs engage LAIR1 with different binding angles. RIFIN activation of LAIR1 induces LAIR1-mediated cell signaling, and LAIR1-containing antibodies can block this pathway.\",\n      \"method\": \"X-ray crystallography of RIFIN-LAIR1 complexes, functional cell signaling assay, antibody blocking assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of two independent complexes plus functional signaling validation; confirmed by independent structural study (PMID 34244481)\",\n      \"pmids\": [\"34433057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Structures of RIFIN-V2 domain in complex with LAIR1 domain were determined by crystallography. The LAIR1-binding region of RIFIN is hydrophobic and membrane-distal, exhibits extensive structural diversity, and interacts with RIFIN-V2 in a one-to-one fashion. Essential elements of RIFIN-binding on LAIR1 were identified.\",\n      \"method\": \"Negative-stain EM, X-ray crystallography, sequence/structure analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures plus EM architecture determination in a single rigorous study\",\n      \"pmids\": [\"34244481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LAIR-1 activation inhibits M1-like macrophage polarization and promotes alternative (M2) activation in human THP-1 macrophages. IFN-γ reduces LAIR-1 expression in THP-1 macrophages. IL-4 has no effect on LAIR-1 expression.\",\n      \"method\": \"THP-1 macrophage polarization model, cytokine treatment, LAIR-1 activation by cross-linking, phenotypic analysis\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional polarization assay, single lab, single cell line model\",\n      \"pmids\": [\"29887420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Silencing LAIR-1 in THP-1 macrophages modulates the SHP-1/CREB/PPARγ pathway, promoting M2 macrophage polarization and increasing foam cell formation. LAIR-1 signaling through SHP-1 and CREB controls PPARγ expression and cholesterol metabolism.\",\n      \"method\": \"siRNA silencing of LAIR-1, western blotting for SHP-1/CREB activation, Oil Red O staining for foam cell formation, qPCR for PPARγ and cholesterol metabolism genes\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple pathway readouts, single lab\",\n      \"pmids\": [\"30176557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LAIR1 drives glioma progression through SHP2-mediated FAK nuclear localization, resulting in increased transcription of cyclin D1 and chemokines/cytokines (CCL5, TGFβ2, IL33). The LAIR1 ITIMs recruit SHP2, which interacts with FAK and induces FAK nuclear localization. LAIR1Y251/281F (ITIMs mutant) and SHP2Q510E mutants significantly reduced FAK nuclear localization and target gene expression.\",\n      \"method\": \"Co-immunoprecipitation, nuclear/cytoplasm fractionation, ITIM mutagenesis, in vitro and in vivo glioma growth assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus mutagenesis with functional readouts, single lab\",\n      \"pmids\": [\"37845206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Globular domain of adiponectin (gAdp) interacts with LAIR-1. In vitro experiments showed that gAdp inhibits T cell activation via LAIR-1 through a process involving downstream SHP-2.\",\n      \"method\": \"Pulldown/binding assay, T cell activation inhibition assay, SHP-2 downstream signaling analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single binding and functional experiment, single lab, limited mechanistic depth\",\n      \"pmids\": [\"34403808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"C1q can crosslink CD33 and LAIR-1 simultaneously and concurrently activate both inhibitory motifs. The globular region of C1q binds CD33, while the collagen-like region binds LAIR-1. Sialic acid masking of CD33 C2 domains regulates C1q-CD33 interactions.\",\n      \"method\": \"Binding assays, ITIM phosphorylation assay, siRNA-mediated knockdown, competition experiments with C1q domains\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain dissection with competition assays and ITIM phosphorylation readouts, single lab\",\n      \"pmids\": [\"28325905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LAIR-1 inhibits osteoclastogenesis. Anti-LAIR-1 antibody treatment inhibits multinucleated osteoclast formation from mouse bone marrow cells in vitro. LAIR-1 overexpression in CD14+ monocytes also inhibits human osteoclastogenesis in vitro.\",\n      \"method\": \"Anti-LAIR-1 antibody treatment of bone marrow cultures, LAIR-1 overexpression in human monocytes, osteoclast differentiation assay\",\n      \"journal\": \"Clinics (Sao Paulo, Brazil)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both antibody blockade and overexpression approaches in two species, single lab\",\n      \"pmids\": [\"23778340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Trophoblasts and decidual stromal cells regulate decidual NK cell function via secretion of collagen, which interacts with LAIR-1 on dNKs. Co-culture of dNKs with HTR-8/DSCs upregulates LAIR-1 and decreases perforin expression and Th1-type cytokine production. These effects are abrogated by LAIR-2 (competitive LAIR-1 inhibitor) and by collagen knockdown via shRNA.\",\n      \"method\": \"Co-culture assay, flow cytometry, ELISA for cytokines, shRNA knockdown of collagen, LAIR-2 competition assay\",\n      \"journal\": \"American journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple intervention approaches (LAIR-2 competition, shRNA), functional NK cell readouts, single lab\",\n      \"pmids\": [\"24548186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LAIR-1 agonism by a therapeutic antibody (NC525) induces cell death of leukemic stem cells (LSCs) but not healthy hematopoietic stem cells. LAIR-1 agonism drives a unique apoptotic signaling program in leukemic cells, enhanced in the presence of collagen.\",\n      \"method\": \"Anti-LAIR-1 agonist antibody treatment, cell viability assays, cell-derived and patient-derived xenograft models, apoptosis signaling analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — agonist antibody with multiple in vitro and in vivo xenograft models, selectivity for LSC vs HSC demonstrated\",\n      \"pmids\": [\"37966113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In HEL cells with JAK2 V617F mutation, LAIR-1 engagement with collagen recruits SHP-2, which downregulates tyrosine phosphorylation of JAK2, STAT1, STAT3, STAT5, AKT, and mTOR, thereby inhibiting cell proliferation and promoting apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, western blotting for phosphorylation of pathway components, CCK-8 proliferation assay, flow cytometry apoptosis assay\",\n      \"journal\": \"Xi bao yu fen zi mian yi xue za zhi\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus multiple pathway phosphorylation assays with functional readouts, single lab\",\n      \"pmids\": [\"38512030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LAIR1 increases PD-L1 expression in HCC cells through the GSK-3β/β-catenin/MYC/PD-L1 pathway, inducing exhaustion of infiltrating CD8+ T cells. LAIR1 in HCC cells induces phosphorylation of GSK-3β, impairing β-catenin expression and nuclear localization, thereby reducing MYC-mediated PD-L1 suppression and ultimately upregulating PD-L1.\",\n      \"method\": \"Western blot, immunofluorescence, nucleus/cytoplasm fractionation, co-culture of HCC cells with CD8+ T cells, flow cytometry for T cell exhaustion markers\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway assays with co-culture functional readout, single lab\",\n      \"pmids\": [\"38199599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MARCO is a ligand for LAIR-1. MARCO interacts with LAIR-1 in trans on NK cells and induces LAIR-1 inhibitory signaling. MARCO and LAIR-1 also interact in cis on THP-1 macrophages (demonstrated by single-molecule fluorescence microscopy), reducing LAIR-1 binding to collagen and dampening LAIR-1 signaling. CRISPR-Cas9 knockout of MARCO in IL-10-polarized macrophages increases LAIR-1-mediated inhibitory function.\",\n      \"method\": \"Binding assays, LAIR-1 signaling assay on NK cells, single-molecule fluorescence microscopy, CRISPR-Cas9 knockout, collagen binding assay\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (single-molecule imaging, CRISPR KO, binding assays, functional signaling assay) in single rigorous study\",\n      \"pmids\": [\"41364749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LAIR1 in HCC cells promotes migration and invasion through the AKT-IKKβ-p65 axis. LAIR1 also induces alternative activation and infiltration of tumor-associated macrophages via upregulation of IL-6 and CCL5 within this axis.\",\n      \"method\": \"Transwell/scratch migration assay, transcriptome sequencing, western blot, nucleus/cytoplasm fractionation, ELISA, cytokine microarray\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including transcriptome sequencing and functional migration assays, single lab\",\n      \"pmids\": [\"39016636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LAIR-1 and PECAM-1 act to inhibit GPVI-mediated platelet activation via the same signaling pathway. LAIR-1/PECAM-1 double KO mice show platelets equally hyperresponsive to collagen as single KO mice. The enhanced Src family kinase activation previously shown in LAIR-1-deficient single KO mice is absent in DKO mice, suggesting functional redundancy through a shared pathway.\",\n      \"method\": \"LAIR-1/PECAM-1 double knockout mouse model, platelet aggregometry, flow cytometry, western blotting for Src signaling, FeCl3 thrombosis model\",\n      \"journal\": \"Research and practice in thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic double KO epistasis analysis with multiple functional and signaling readouts in vivo and in vitro\",\n      \"pmids\": [\"39318773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PTIC (polymerized type I collagen) binds LAIR1 with affinity similar to collagen (confirmed by surface plasmon resonance). PTIC engagement of LAIR1 downregulates pSTAT1 (Tyr701) in IFN-γ-induced M1 macrophages, and reduces Mo1 monocyte subsets and associated cytokines in COVID-19 patients.\",\n      \"method\": \"Surface plasmon resonance binding assay, western blotting for pSTAT1, flow cytometry, clinical sample analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SPR binding confirmation plus functional signaling assay, single lab\",\n      \"pmids\": [\"39940787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In fibrotic disease (systemic sclerosis), fibroblasts deposit disorganized collagen products that are dysfunctional LAIR-1 ligands, due to matrix metalloproteinase and PDGFR-dependent collagen remodeling. LAIR-1-deficient mice show increased skin fibrosis in two models, demonstrating that LAIR-1 is an essential negative feedback mechanism for tissue repair.\",\n      \"method\": \"LAIR-1 KO mouse models (repeated injury and bleomycin), fibroblast collagen deposition assay, MMP and PDGFR inhibitor experiments, LAIR-1 binding to patient-derived fibroblast matrix\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in two independent mouse models plus mechanistic dissection in vitro with pharmacological inhibitors\",\n      \"pmids\": [\"38696927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LAIR-1 suppresses ovarian cancer cell growth by inhibiting the PI3K-AKT-mTOR axis. Co-IP and mass spectrometry identified potential LAIR-1-binding proteins including eukaryotic translation initiation factors, suggesting LAIR-1 may also regulate protein synthesis at the translational level.\",\n      \"method\": \"LAIR-1 overexpression in SKOV3 cells, proliferation/migration/apoptosis assays, western blotting for PI3K/AKT/mTOR, Co-IP with mass spectrometry, in vivo tumor model\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS plus functional pathway assays in vitro and in vivo, single lab\",\n      \"pmids\": [\"32628130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TNF-α stimulation causes shedding of cell-surface LAIR-1 from fibroblast-like synoviocytes via serine proteases. This shedding can be blocked by serine protease inhibitors. LAIR-1 overexpression in FLS reduces invasion and decreases mRNA levels of IL-6, IL-8, and MMP-13 in the presence of TNF-α.\",\n      \"method\": \"Flow cytometry for membrane LAIR-1, protease inhibitor experiments, qPCR, transwell invasion assay\",\n      \"journal\": \"Clinical and experimental immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological intervention identifying serine protease mechanism of shedding, plus functional invasion assay, single lab\",\n      \"pmids\": [\"29328500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LAIR-1 inhibition (KO, antibody blockade, or 3-in-1 CAR) uncovered a LAIR1/factor XIII A/collagen IV immunosuppressive pathway across cancer types. LAIR1 inhibition induced phenotypic shift of M2-like macrophages toward M1 and enhanced CD8+ memory T cell populations, normalized tumor collagen IV in the TME.\",\n      \"method\": \"LAIR-1 KO mice, anti-LAIR-1 antibody blockade, 3-in-1 CAR T cell design, tumor models, flow cytometry, pathway analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological interventions identifying a novel LAIR1/factor XIIIA/collagen IV pathway, single lab\",\n      \"pmids\": [\"40591413\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LAIR-1 (CD305) is a broadly expressed immune inhibitory receptor with a single extracellular Ig-like domain and two cytoplasmic ITIMs that, upon engagement by extracellular matrix collagens (binding dependent on Gly-Pro-Hyp repeats), C1q (via its collagen-like tail), adiponectin globular domain, Colec12, or MARCO, recruits and activates the phosphatases SHP-1 and SHP-2, thereby dampening activating signals across NK cells, T cells, B cells, monocytes, dendritic cells, ILC2s, neutrophils, and megakaryocytes; in AML stem cells it additionally uses SHP-1 as a phosphatase-independent adaptor to recruit CAMK1 and activate CREB for survival/self-renewal, while in glioma and HCC tumor cells it recruits SHP2 to drive FAK nuclear localization and pro-tumorigenic transcriptional programs, and in megakaryocytes it restrains Src kinase activity in the same pathway as PECAM-1 to limit platelet reactivity; LAIR-2, a secreted homolog with higher collagen affinity, acts as a natural competitive antagonist of LAIR-1.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LAIR-1 (CD305) is a broadly expressed transmembrane immune inhibitory receptor with a single Ig-like domain and a cytoplasmic tail bearing two ITIMs that, upon cross-linking, recruits the phosphatases SHP-1 and SHP-2 to dampen activating signals — first established as a potent inhibitor of NK cell cytotoxicity [#0]. Its defining feature is recognition of extracellular matrix: collagens are high-affinity functional ligands whose binding depends on Gly-Pro-Hyp repeats and engages a binding surface (R59, E61, W109) structurally analogous to the platelet collagen receptor GPVI [#1, #2]. Through this collagen sensing, LAIR-1 imposes inhibitory tone across diverse cell types — restraining BCR signaling in B cells, monocyte-to-DC differentiation, type I IFN production, ILC2 effector function via SHP1/PI3K/AKT, neutrophil recruitment, and osteoclastogenesis [#3, #6, #14, #15, #13]. Beyond collagen, LAIR-1 is engaged by additional collagen-domain or stromal ligands including C1q (via its collagen-like tail), Colec12, adiponectin globular domain, MARCO, and polymerized type I collagen, with the secreted homolog LAIR-2 acting as a high-affinity competitive antagonist [#5, #6, #12, #24, #31, #34]. In the tissue setting LAIR-1 functions as a negative-feedback brake on tumor immunity and fibrosis: collagen-induced exhaustion of CD8+ T cells proceeds through LAIR1/SHP-1, and loss of functional collagen ligands in systemic sclerosis exacerbates fibrosis [#11, #35]. In cancer cells LAIR-1 is co-opted for pro-tumorigenic signaling — in AML stem cells SHP-1 acts as a phosphatase-independent adaptor recruiting CAMK1 to activate CREB for survival and self-renewal, while in glioma it recruits SHP2 to drive FAK nuclear localization and oncogenic transcription [#7, #23]. In megakaryocytes LAIR-1 restrains GPVI-FcRγ-driven Src family kinase activity in a pathway redundant with PECAM-1, limiting platelet reactivity [#10, #33]. The malaria RIFIN antigens engage LAIR1 at a site overlapping the collagen-binding surface, and somatic insertion of the LAIR1 collagen-binding domain into antibody genes generates broadly reactive anti-RIFIN antibodies [#16, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established LAIR-1 as an HLA-independent inhibitory receptor, answering whether its ITIMs functionally couple to phosphatases and suppress effector function.\",\n      \"evidence\": \"Antibody cross-linking on NK cells with phosphatase recruitment and cytotoxicity assays\",\n      \"pmids\": [\"9285412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ligand unknown at this point\", \"Relative roles of SHP-1 vs SHP-2 not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Extended LAIR-1 inhibitory function to B cell antigen receptor signaling and showed activation-dependent downregulation, defining its role across lymphocyte lineages.\",\n      \"evidence\": \"Co-cross-linking with BCR and intracellular calcium flux measurement plus expression profiling\",\n      \"pmids\": [\"10540327\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors in B cells not delineated\", \"Single lab\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed LAIR-1 blocks myeloid differentiation by inhibiting GM-CSF receptor signaling, broadening its inhibitory scope to monocyte/DC development.\",\n      \"evidence\": \"Antibody cross-linking with monocyte-DC differentiation and calcium measurement\",\n      \"pmids\": [\"9692876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link to GM-CSFR signaling not molecularly defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified collagens as the first ECM ligands for an inhibitory immune receptor, answering the long-standing question of LAIR-1's physiological ligand.\",\n      \"evidence\": \"Cell-free and cell-surface binding assays with Gly-Pro-Hyp dependence and functional immune assays\",\n      \"pmids\": [\"16754721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of recognition not yet defined\", \"In vivo relevance of collagen engagement untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the structural basis of collagen recognition and revealed an unexpected shared mechanism with the platelet receptor GPVI.\",\n      \"evidence\": \"X-ray crystallography, NMR titrations, and site-directed mutagenesis identifying R59/E61/W109\",\n      \"pmids\": [\"20007810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of receptor-ligand complex not solved\", \"Conformational changes on engagement unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the secreted homolog LAIR-2 as a higher-affinity competitive antagonist, establishing a natural mechanism for tuning LAIR-1 signaling.\",\n      \"evidence\": \"SPR, flow cytometry binding, adhesion, and cross-linking inhibition assays\",\n      \"pmids\": [\"18209062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo regulatory role of LAIR-2 not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Broadened the LAIR-1 ligand repertoire to C1q via its collagen-like tail, linking complement to inhibitory signaling in myeloid cells.\",\n      \"evidence\": \"Binding assays, ITIM phosphorylation, siRNA knockdown, and functional DC/IFN-α assays\",\n      \"pmids\": [\"23093673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mode of C1q binding not yet defined here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a non-canonical, phosphatase-independent LAIR1-SHP-1-CAMK1-CREB axis sustaining AML stem cell survival, recasting an inhibitory receptor as a tumor dependency.\",\n      \"evidence\": \"shRNA knockdown, in vivo leukemia assays, Co-IP, and signaling pathway analysis\",\n      \"pmids\": [\"25915125\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand driving the AML pathway not defined\", \"How SHP-1 switches from phosphatase to adaptor unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that LAIR-1 restrains GPVI-FcRγ Src kinase signaling in megakaryocytes to limit platelet hyperreactivity and thrombosis.\",\n      \"evidence\": \"LAIR-1 KO mouse with platelet counts, proplatelet formation, Src activity, and in vivo thrombosis model\",\n      \"pmids\": [\"28336561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous activating ligand in megakaryocytes not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established collagen-LAIR1-SHP-1 as a driver of CD8+ T cell exhaustion and a checkpoint-resistance mechanism, linking matrix to anti-tumor immunity.\",\n      \"evidence\": \"Proteomic/RNA profiling, murine tumor models, LAIR2 overexpression, SHP-1 inhibition, LOXL2 knockdown\",\n      \"pmids\": [\"32908154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of T-cell-intrinsic vs stromal LAIR1 not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the LAIR1 interactome including Colec12 and extended its myeloid role to monocyte/macrophage homeostasis, while structural studies mapped C1q and RIFIN engagement.\",\n      \"evidence\": \"Proteomic interactome, Lair1-/- mice, flow cytometry; crystallography of RIFIN-LAIR1 complexes and C1q CLR mutagenesis\",\n      \"pmids\": [\"34260887\", \"34066122\", \"34433057\", \"34244481\", \"34144112\", \"34403808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all newly identified ligands engage overlapping surfaces incompletely resolved\", \"Adiponectin (gAdp) interaction rests on a single weaker study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed that the LAIR1 collagen-binding domain inserted into antibody genes confers broad anti-RIFIN reactivity, revealing pathogen exploitation and a novel antibody architecture.\",\n      \"evidence\": \"Monoclonal antibody isolation, antibody gene sequencing, domain mutagenesis, and erythrocyte/RIFIN binding; later Fab crystallography\",\n      \"pmids\": [\"26700814\", \"28527239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Frequency and selection of such insertions in the population not addressed here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed LAIR1 drives glioma progression via SHP2-mediated FAK nuclear localization and oncogenic transcription, and that agonist antibodies selectively kill leukemic stem cells.\",\n      \"evidence\": \"Co-IP, ITIM mutagenesis, fractionation, glioma models; agonist antibody NC525 with xenograft models\",\n      \"pmids\": [\"37845206\", \"37966113\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Glioma mechanism from single lab\", \"Generality of pro-tumor SHP2-FAK axis across tumor types untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established LAIR-1 as an essential negative-feedback brake on tissue repair and demonstrated functional redundancy with PECAM-1 in platelet signaling.\",\n      \"evidence\": \"LAIR-1 KO fibrosis models with MMP/PDGFR dissection; LAIR-1/PECAM-1 double KO epistasis with platelet aggregometry and Src signaling\",\n      \"pmids\": [\"38696927\", \"39318773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How disorganized fibrotic collagen loses LAIR-1 ligand activity at structural level not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Delineated multiple tumor-cell-intrinsic LAIR1 signaling axes (GSK-3β/β-catenin/MYC/PD-L1; AKT-IKKβ-p65; SHP-2/JAK2-STAT) coupling LAIR1 to immune evasion and proliferation control.\",\n      \"evidence\": \"Western blot, fractionation, co-culture with CD8+ T cells, Co-IP, and migration/proliferation assays in HCC and HEL cells\",\n      \"pmids\": [\"38199599\", \"39016636\", \"38512030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each axis defined in a single lab/model\", \"Reconciliation of inhibitory vs pro-tumor outcomes context-dependent\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified MARCO as a bidirectional cis/trans regulator of LAIR-1 and confirmed polymerized collagen (PTIC) as a functional ligand, expanding the ligand and regulatory landscape.\",\n      \"evidence\": \"Single-molecule fluorescence microscopy, CRISPR-Cas9 KO, binding and signaling assays; SPR and pSTAT1 readouts for PTIC\",\n      \"pmids\": [\"41364749\", \"39940787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of cis MARCO-LAIR1 regulation not established\", \"PTIC therapeutic studies single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LAIR-1 switches between classical SHP-1/SHP-2-dependent inhibition and the phosphatase-independent or pro-tumorigenic signaling modes — and what determines this choice across cell types and ligands — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking ligand identity to SHP-1-adaptor vs phosphatase output\", \"Structural basis of multi-ligand competition (collagen, C1q, MARCO, RIFIN) on one Ig domain incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 31, 37]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 11, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 7, 23]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [10, 33]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SHP-1\", \"SHP-2\", \"C1q\", \"Colec12\", \"MARCO\", \"CAMK1\", \"FAK\", \"PECAM-1\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}